PHASE 3 TRIAL OF TUMOR TREATING FIELDS CONCOMITANT WITH WEEKLY PACLITAXEL FOR PLATINUM-RESISTANT OVARIAN CANCER: ENGOT-OV50/GOG-329/INNOVATE-3

被引：0
|
作者：
Vergote, I. [1 ]
Salutari, V. [2 ]
Cibula, D. [3 ]
Korach, J. [4 ]
Samartzis, E. P. [5 ]
Sehouli, J. [6 ]
Fossati, R. [7 ]
Martin, A. G. [8 ]
Tsibulak, I. [9 ]
Slomovitz, B. [10 ]
Coleman, R. [11 ]
Monk, B. [12 ]
Thaker, P. [13 ]
O'Malley, D. [14 ]
机构：
[1] Leuven Canc Inst, Leuven, Belgium
[2] Fdn Policl Univ Agostino Gemelli, Rome, Italy
[3] Charles Univ Hosp, Prague, Czech Republic
[4] Chaim Sheba Med Ctr, Ramat Gan, Israel
[5] Univ Spital Zurich, Zurich, Switzerland
[6] Charite Frauenklinik, Berlin, Germany
[7] IRCCS Ist Ric Farmacol, Milan, Italy
[8] Clin Univ Navarra, Navarra, Spain
[9] Med Univ Innsbruck, Innsbruck, Austria
[10] Univ Miami, Sylvester Comprehens Canc Ctr, Coral Gables, FL 33124 USA
[11] MD Anderson Canc Ctr, Houston, TX USA
[12] Univ Arizona, Coll Med, Tucson, AZ 85721 USA
[13] Washington Univ Gynecol Oncol, Washington, DC USA
[14] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2020年 / 30卷
关键词：
D O I：
10.1136/ijgc-2020-IGCS.308
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IGCS20_138
引用
收藏
页码：A147 / A148
页数：2
相关论文
共 50 条
  • [21] Targeting AXL in platinum-resistant ovarian cancer: from the lab bench to Phase 3 trial
    Fuh, Katherine
    CANCER RESEARCH, 2024, 84 (05)
  • [22] Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
    Alqaisi, Husam A.
    Cohn, David E.
    Chern, Jing-Yi
    Duska, Linda R.
    Jewell, Andrea
    Corr, Bradley R.
    Winer, Ira Seth
    Girda, Eugenia
    Crispens, Marta A.
    Dhani, Neesha C.
    Madariaga, Ainhoa
    Grant, Robert C.
    Malaguti, Matthew
    Lee, Crystal
    Bowering, Valerie
    Wong, Horace
    Poothullil, Andrew
    Speers, Vanessa
    Wang, Lisa
    Bedard, Philippe L.
    Brady, John C.
    Nixon, Andrew B.
    Chen, Li
    O'Connor, Claire
    Zamboni, William
    Mckee, Tawyna
    Moscow, Jeffrey A.
    Oza, Amit M.
    Lheureux, Stephanie
    CLINICAL CANCER RESEARCH, 2025, 31 (06) : 993 - 1001
  • [23] Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial
    Pignata, Sandro
    Lorusso, Domenica
    Scambia, Giovanni
    Sambataro, Daniela
    Tamberi, Stefano
    Cinieri, Saverio
    Mosconi, Anna M.
    Orditura, Michele
    Brandes, Alba A.
    Arcangeli, Valentina
    Panici, Pierluigi Beneditti
    Pisano, Carmela
    Cecere, Sabrina C.
    Di Napoli, Marilena
    Raspagliesi, Francesco
    Maltese, Giuseppa
    Salutari, Vanda
    Ricci, Caterina
    Daniele, Gennaro
    Piccirillo, Maria Carmela
    Di Maio, Massimo
    Gallo, Ciro
    Perrone, Francesco
    LANCET ONCOLOGY, 2015, 16 (05): : 561 - 568
  • [24] AXLerate-OC/GOG-3059/ENGOT OV-66: Results of a phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept (AVB-S6-500) in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer
    Fuh, Katherine Cynthia
    Tsitsishvili, Zaza
    Reid, Thomas J.
    De Giorgi, Ugo
    Hand, Lauren
    Bowen, Rebecca
    Miller, Devin
    Vulsteke, Christof
    Sharma, Sudarshan K.
    Chudecka-Glaz, Anita M.
    Liu, Joyce F.
    Eberst, Lauriane
    Neff, Robert
    Lim, Peter C.
    Iglesias, David A.
    Jenkins Vogel, Tilley
    Myers, Tashanna K. N.
    Gonzalez-Martin, Antonio
    Gonzalez Martin, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA5515 - LBA5515
  • [25] A phase 3, randomized, double-blind, adaptive, placebo/paclitaxel-controlled study of AVB-S6-500 in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer (GOG-3059/ENGOT OV-66/AVB500-OC-004).
    Fuh, Katherine Cynthia
    Herzog, Thomas J.
    Moore, Kathleen N.
    Myers, Tashanna K. N.
    Rimel, B. J.
    Liu, Joyce F.
    Secord, Angeles Alvarez
    Hamilton, Erika P.
    Reid, Thomas J.
    Lewin, Sharyn Nan
    Mullen, Mary M.
    Mills, Kathryn A.
    Anderson, Randy
    Rangwala, Reshma A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [26] Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial
    Moreno, Victor
    Barretina-Ginesta, Maria-Pilar
    Garcia-Donas, Jesus
    Jayson, Gordon C.
    Roxburgh, Patricia
    Vazquez, Raul Marquez
    Michael, Agnieszka
    Anton-Torres, Antonio
    Brown, Richard
    Krige, David
    Champion, Brian
    McNeish, Iain
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (12)
  • [27] ARTISTRY-7: A PHASE 3, MULTICENTER STUDY OF NEMVALEUKIN ALFA IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN PATIENTS WITH PLATINUM-RESISTANT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER (GOG-3063; ENGOT-OV68)
    Sehouli, Jalid
    Hays, John L.
    Barlin, Joyce N.
    Buscema, Joseph
    Cloven, Noelle G.
    Kong, Lynn R.
    Tyagi, Nidhi Kumar
    Lanneau, Grainger S.
    Long, Beverly J.
    Marsh, Robert L.
    Seward, Shelly M.
    Starks, David C.
    Welch, Stephen
    Moore, Kathleen N.
    Konstantinopoulos, Panagiotis A.
    Gilbert, Lucy
    Monk, Bradley J.
    O'Malley, David M.
    Coleman, Robert L.
    Herzog, Thomas J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A416 - A416
  • [28] ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (GOG-3063; ENGOT-OV68)
    Herzog, Thomas J.
    Hays, John L.
    Barlin, Joyce N.
    Buscema, Joseph
    Cloven, Noelle Gillette
    Kong, Lynn R.
    Tyagi, Nidhi Kumar
    Lanneau, Grainger
    Long, Beverly J.
    Marsh, Robert L.
    Seward, Shelly Marie
    Starks, David
    Welch, Stephen
    Moore, Kathleen N.
    Konstantinopoulos, Panagiotis A.
    Gilbert, Lucy
    Monk, Bradley J.
    O'Malley, David M.
    Coleman, Robert L.
    Sehouli, Jalid
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] UPLIFT (ENGOT-ov67/GOG-3048): Results from the phase II trial of upifitamab rilsodotin, a NaPi2b-directed dolaflexin antibody-drug conjugate, in platinum-resistant ovarian cancer
    Richardson, Debra
    Iyer, Gopa
    Schmid, Anita
    Palma, Norma
    Navarro, Willis
    Ahnert, Jordi Rodon
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S285 - S286
  • [30] ENGOT-ov65/KEYNOTE-B96: Phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer.
    Colombo, Nicoletta
    Coleman, Robert L.
    Wu, Xiaohua
    Kose, Fatih
    Wenham, Robert Michael
    Sebastianelli, Alexandra
    Hasegawa, Kosei
    Zsiros, Emese
    Rouge, Thibault De la Motte
    Bidzinski, Mariusz
    McNeish, Iain A.
    Sehouli, Jalid
    Korach, Jacob
    Debruyne, Philip R.
    Kim, Jae-Weon
    De Melo, Andrea C.
    Peng, Xuan
    Bogusz, Agata M.
    Yamada, Karin Sayuri
    Monk, Bradley J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345